Brief: Opus Genetics Announces FDA Acceptance Of Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% For The Treatment Of Presbyopia
25/02/2026 12:00
Feb 25 (Reuters) - Opus Genetics Inc IRD.O: OPUS GENETICS ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% FOR THE TREATMENT OF PRESBYOPIA OPUS GENETICS INC - FDA SETS PDUFA DATE FOR OCTOBER 17, 2026 Source text: ID:nGNXb2CN1w Further company coverage: IRD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data